Lido Advisors
AKBA icon

Lido Advisors’s Akebia Therapeutics AKBA Stock Holding History

Lido Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-47,686
Closed -$390K – 537
2019
Q1 		$390K Buy
47,686
+9,986
+26% +$68.5K 0.03% 333
2018
Q4 		$208K Buy
37,700
+4,518
+14% +$35.4K 0.02% 394
2018
Q3 		$292K Buy
33,182
+5,050
+18% +$45.2K 0.03% 340
2018
Q2 		$280K Buy
28,132
+13,922
+98% +$139K 0.03% 323
2018
Q1 		$135K Buy
+14,210
New +$199K 0.02% 385

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lido Advisors's AKBA Position: Q2 2019 in Review

Lido Advisors sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 47,686 shares — an estimated $390K sold.

Lido Advisors first reported a position in AKBA in Q1 2018 and held it in 5 quarters. The position peaked at $390K in Q1 2019. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Lido Advisors reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Lido Advisors sold 47,686 Akebia Therapeutics shares in Q2 2019, an estimated $390K.
  • Lido Advisors first reported a position in Akebia Therapeutics in Q1 2018 and held it in 5 quarters.
  • Lido Advisors's Akebia Therapeutics position peaked at $390K in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Lido Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.